Explore Goddess Protocol RxRx care

Bremelanotide (PT-141)

Ingredient · In our PT-141 Injection

Bremelanotide (PT-141), the active ingredient in Vyleesi

Most sexual health medicines work on blood flow. Bremelanotide works in the brain instead, on pathways linked to desire. The brand version is FDA-approved for low desire before menopause.1

Abstract rose optical caustics, illustrative ingredient artwork
Bremelanotide

Photo is an illustration, not the medicine. Bremelanotide is made in a lab.

FDA-approved before menopause

Brand-name bremelanotide (Vyleesi) is FDA-approved for premenopausal women with low sexual desire that causes distress. The label says it is not approved for women after menopause, so use after menopause is off-label.1 Our PT-141 is compounded by a licensed pharmacy, and compounded versions are not FDA-approved.3

FDA-approved for this useWell studied, used off-labelEarly evidenceLittle or no human data

The studies below used FDA-approved products or other forms. Our compounded version hasn't been studied in trials, and results may differ.

What it is

Bremelanotide is a small peptide that activates melanocortin receptors, part of the brain's own system for desire and arousal. It's taken as an injection about 45 minutes before you expect to want it, rather than every day.1

Why it's in this product

Low desire that bothers you is real, common and worth a conversation. Bremelanotide is FDA-approved to treat it before menopause, and it's taken only when needed rather than every day.1 It's in this product for women who want to explore that option with a clinician.

PT-141 Injection

What the studies in people show

  • Two randomized trialsMore desire, less distress, before menopauseIn two 24-week trials with 1,267 premenopausal women (average age 39), FDA-approved Vyleesi (bremelanotide) modestly increased sexual desire and reduced distress about low desire compared with placebo.2 Nausea, flushing and headache were more common than with placebo.
  • FDA labelNausea is the big oneIn the trials, 40% of women on bremelanotide had nausea, 13% needed anti-nausea medicine and 8% stopped because of it. For most, nausea improved with the second dose.1

What we don't know yet

The approval trials were in premenopausal women. Whether bremelanotide helps after menopause hasn't been shown in trials of the same quality, which is why that use is off-label.1 Compounded versions also haven't been compared head to head with the brand.3

Safety, in plain English

Besides nausea, common side effects include flushing, injection site reactions, headache and vomiting. Blood pressure rises a little and heart rate dips after each dose, usually settling within 12 hours, so it isn't used by people with uncontrolled high blood pressure or heart disease. The label advises no more than one dose in 24 hours and no more than 8 a month; more frequent use raises the chance of dark patches on the skin.1

A licensed clinician reviews your health history and decides whether it's appropriate for you. Exploring it here never means you'll get a prescription.

Curious about PT-141 Injection?

Start with a free assessment. A licensed clinician reviews your health history and decides whether treatment is appropriate. No pressure, and no prescription unless it makes sense for you.

See PT-141 InjectionHow care works

Sources

  1. U.S. National Library of Medicine, DailyMed. Vyleesi (bremelanotide) injection: prescribing information. DailyMed
  2. Kingsberg SA, Clayton AH, Portman D, et al. Bremelanotide for the treatment of hypoactive sexual desire disorder: two randomized phase 3 trials. Obstet Gynecol. 2019;134:899-908. PubMed 31599840
  3. U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers. FDA

Sources checked November 8, 2026. This page is general education, not medical advice, and it doesn't mean any treatment is right for you. Photos: Unsplash (giovanni cordioli).